We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Physiomics Announces License Agreement with Eli Lilly
News

Physiomics Announces License Agreement with Eli Lilly

Physiomics Announces License Agreement with Eli Lilly
News

Physiomics Announces License Agreement with Eli Lilly

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Physiomics Announces License Agreement with Eli Lilly"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Physiomics, the Oxford, UK based systems biology company has announced that it has signed a license agreement with Eli Lilly and Company.

Under the terms of the agreement, Physiomics will license to Lilly a customized version of its ModelPlayer for in silico simulations of unspecified anticancer drugs and Lilly will have the option to purchase additional licenses.

According to Physiomics, its ModelPlayer is a stand-alone simulation platform used for in-house model development that can be out-licensed to partners to allow them to perform their own simulations using Physiomics’ models. It incorporates a range of features necessary for developing and calibrating models and simulating anticancer drugs.

Dr Christophe Chassagnole, COO of Physiomics, said: ‘We are delighted with the continued interest shown by Lilly in Physiomics’ technology. We hope that the capability for Lilly scientists to directly use Physiomics’ models will strengthen the quality of the interactions within our ongoing research collaborations. This is also an important commercial and technical milestone for Physiomics as this is the first time that we have out-licensed our technology.’
Advertisement